Jazz Pharmaceuticals announced that Philip Johnson has been appointed Executive Vice President and CFO, effective March 1. Johnson succeeds Renee Gala, who was promoted to President and Chief Operating Officer in October 2023. Johnson joins Jazz Pharmaceuticals with over 35 years of financial experience, most recently leading Eli Lilly and Company’s treasury and investor relations operations as Group Vice President of Finance. In his new role, Mr. Johnson will oversee financial reporting, accounting, tax, treasury, risk management, financial planning and analysis, information services and facilities. He will also oversee the Company’s investor relations and corporate development functions.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on JAZZ:
- Jazz to acquire KRAS inhibitor program from Redx Pharma for $10M upfront
- Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program
- Jazz Pharmaceuticals price target lowered to $235 from $240 at Barclays
- Jazz Pharmaceuticals Incurs New Financial Obligations
- Jazz Pharmaceuticals Revises Loan Terms with Lenders
